Nevertheless, the careful implication of targeting eIF2α phosphorylation could strategically overcome the risk of global translation inhibition and help develop novel translation inhibitors that can be used for anticancer therapies for eIF2-associated cancer types. The gene discussed is EIF2S3; the disease is cancer.